title: Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.
abstract: In this study, we investigated the yeasts colonization of genus Candida, including C. dubliniensis, isolated of HIV-infected patients oral cavities and we accessed in vitro susceptibility pattern of the Candida isolates to four antifungal agents. Out of 99 patients investigated, 62 (62.6%) were colonized with yeasts. C. albicans was the prevailing species (50%). C. dubliniensis isolates were not recovered in our study. We verified that 8.1% of the yeasts isolated were resistant to fluconazole, 8.1% to itraconazole and 3.2% to voriconazole. The isolates demonstrated very low voriconazole MICs, in which 79% (49/62) presented values of 0.015 mug/ml. All Candida isolates were susceptible to amphotericin B. The results reported here showed that although C. albicans continues to be present in one-half of oral Candida carriage of HIV-infected patients, Candida non-albicans species are increasing among these patients. Besides, the findings of resistant isolates endorse the role of antifungal susceptibility testing whenever antifungal treatment with azoles is planned.
authors.affiliation: Instituto de Patologia Tropical e Saúde Pública da, Universidade Federal de Goiás, Goiás, Brazil.
authors.forename: Carolina Rodrigues
authors.initials: CR
authors.lastname: Costa
authors.forename: Janine Aquino
authors.initials: JA
authors.lastname: de Lemos
authors.forename: Xisto Sena
authors.initials: XS
authors.lastname: Passos
authors.forename: Crystiane Rodrigues
authors.initials: CR
authors.lastname: de Araújo
authors.forename: Ana Joaquina
authors.initials: AJ
authors.lastname: Cohen
authors.forename: Lúcia Kioko Hasimoto E
authors.initials: LK
authors.lastname: Souza
authors.forename: Maria do Rosário Rodrigues
authors.initials: Mdo R
authors.lastname: Silva
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology*; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification*; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000382:microbiology* / Q000821:virology*; D025141:Drug Resistance, Fungal; D005260:Female; D006678:HIV / Q000254:growth & development*; D015658:HIV Infections / Q000188:drug therapy / Q000382:microbiology* / Q000821:virology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests
chemical_list: D000935:Antifungal Agents